SC5b-9 antibody | 056B-126.96.36.199 (3R2/0)
|Mouse anti Human SC5b-9 antibody, clone 056B-188.8.131.52 (3R2/0) recognizes the SC5b-9 complex of around 330 kDa. Both the classical and alternative complement pathways result in the formation of the cytolysis inducing C5b-9 complex. This complex is composed of 190 kDa C5b which is bound to cells via 71 kDa C9. Sublytic assembly of C5b-9 on plasma membranes induces cell cycle activation and survival. The binding of C5b-9 to the 75 kDa S-protein (or vitronectin) in the fluid phase prevents C5b-9 from assembling on the plasma membrane, deactivating it and forming the SC5b-9 complex. SC5b-9 is stable in vitro and is therefore a reliable indicator of terminal complement pathway activation.
Removal of Sodium Azide is recommended prior to use in functional assays.
Mouse anti Human SC5b-9 antibody, clone 3R2/0 has been reported to work in western blotting applications.
- Target Species
- Product Form
- Purified IgG - liquid
- Purified IgG prepared by affinity chromatography on Protein A from ascites
- Buffer Solution
- Borate buffered saline
- Preservative Stabilisers
- 0.1% Sodium Azide (NaN3)
- Approx. Protein Concentrations
- Current, batch-specific concentration 1.176 mg/ml
- For research purposes only
- Guaranteed until date of expiry. Please see product label.
Avoid repeated freezing and thawing as this may denature the antibody. Storage in frost-free freezers is not recommended.
|Application Name||Verified||Min Dilution||Max Dilution|
|Immunohistology - Frozen|
- Histology Positive Control Tissue
- Kidney from post streptoccal glomerulonephritis patients.
Biesecker, G. (1990) The complement SC5b-9 complex mediates cell adhesion through a vitronectin receptor.
J Immunol. 145 (1): 209-14.
Greenstein, J.D. et al. (1995) The kinetics and distribution of C9 and SC5b-9 in vivo: effects of complement activation.
Clin Exp Immunol. 100 (1): 40-6.
Rus, H. et al. (2005) C5b-9 complement complex in autoimmune demyelination and multiple sclerosis: dual role in neuroinflammation and neuroprotection.
Ann Med. 37 (2): 97-104.
Always be the first to know.
When we launch new products and resources to help you achieve more in the lab.Yes, sign me up